Severe cancer pain substantially affects patients' quality of life, increasing the burden of the
disease and reducing the disability-adjusted life years. Although opioid analgesics are …

Severe cancer pain significantly diminishes patients' quality of life, leading to increased
reliance on caregivers. Although opioid analgesics are effective, they may induce opioid …

Background World Health Organization step III opioids are required to relieve moderate-to-
severe cancer pain; constipation is one of the most frequent opioid-induced side effects. A …

Background Strong opioids, including oxycodone, are the most effective analgesics used to
combat moderate to severe cancer pain, but opioid-induced bowel dysfunction is a relevant …

Background Oxycodone‐naloxone (OXN) aims to reduce opioid‐related constipation while
being successfully analgesic. Methods We evaluated the analgesic response, prevalence …

Opioid analgesics are the cornerstone of pain management for moderate-to-severe cancer
pain and, increasingly, chronic noncancer pain. Despite proven analgesic efficacy, the use …

Background As mentioned by ESMO guidelines on the management of constipation in
advanced cancer, combined opiate/naloxone medications have been shown to reduce the …

Background Oxycodone is a frequently used opioid in cancer. Opioid-induced constipation
(OIC) is common. Oxycodone/Naloxone Prolonged Release (OXN PR) contains naloxone …

Purpose Opioids are associated with side effects in the treatment of moderate-to-severe
chronic cancer pain. Oral combination of opioid agonist-antagonist oxycodone-naloxone …

Purpose Naloxegol, an oral once-daily peripherally acting mu-opioid receptor antagonist, is
indicated for the treatment of opioid-induced constipation (OIC) with inadequate response to …